Furegrelate (sodium)

Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].

Product Specifications

CAS Number

[85666-17-7]

Product Name Alternative

U-63557A

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/furegrelate-sodium.html

Purity

99.82

Solubility

DMSO : 13 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC2=CC(CC3=CC=CN=C3)=CC=C2O1)O[Na]

Molecular Formula

C15H10NNaO3

Molecular Weight

275.23

References & Citations

[1]Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5- (3'-pyridinylmethyl) benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26 (2) :325-42.|[2]Hirenallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2 (2) :193-200.